Core Viewpoint - The market anticipates On Holding (ONON) to report a year-over-year decline in earnings despite an increase in revenues when it releases its quarterly results for the period ending March 2025 [1][2]. Earnings Expectations - On Holding is expected to report earnings of $0.24 per share, reflecting a year-over-year decrease of 36.8% [3]. - Revenue projections stand at $773.88 million, which represents a 33.1% increase compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 0.94% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for On Holding is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +4.17% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP reading is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8]. - On Holding currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, On Holding exceeded the expected earnings of $0.20 per share by delivering $0.38, resulting in a surprise of +90% [12]. - Over the past four quarters, On Holding has beaten consensus EPS estimates two times [13]. Industry Context - In the Zacks Retail - Apparel and Shoes industry, Tapestry (TPR) is expected to report earnings of $0.89 per share for the same quarter, reflecting a year-over-year increase of 9.9% [17]. - Tapestry's revenue is projected to be $1.53 billion, up 3.1% from the previous year [17].

Company Overview - Vivos Therapeutics, Inc. (VVOS) is expected to report a quarterly loss of $0.44 per share, reflecting a year-over-year change of +73% [3] - Revenues are anticipated to be $3.7 million, which is an increase of 8.2% from the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 14.71% lower in the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Vivos is the same as the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [10][11] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, but its predictive power is significant mainly for positive readings [7] - Vivos currently holds a Zacks Rank of 4, making it challenging to predict an earnings beat [11] Historical Performance - In the last reported quarter, Vivos was expected to post a loss of $0.43 per share but actually reported a loss of $0.28, resulting in a surprise of +34.88% [12] - Over the past four quarters, Vivos has beaten consensus EPS estimates two times [13] Industry Comparison - Ironwood Pharmaceuticals (IRWD), another player in the Zacks Medical - Drugs industry, is expected to report a loss of $0.05 per share, indicating a year-over-year change of -150% [17] - Ironwood's revenues are projected to be $59.45 million, down 20.6% from the previous year [17] - The consensus EPS estimate for Ironwood has been revised 28.6% lower in the last 30 days, with an Earnings ESP of -121.05% [18]

Company Overview - Fox Corporation is expected to report quarterly earnings of $0.96 per share, reflecting a year-over-year decline of 11.9% [3] - Revenues are anticipated to reach $4.15 billion, which is an increase of 20.5% compared to the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has been revised 4.84% higher in the last 30 days, indicating a positive reassessment by analysts [4] - The Most Accurate Estimate for Fox is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +4.53% [10][11] - Fox currently holds a Zacks Rank of 2 (Buy), suggesting a strong likelihood of beating the consensus EPS estimate [11] Historical Performance - In the last reported quarter, Fox exceeded the expected earnings of $0.61 per share by delivering $0.96, resulting in a surprise of +57.38% [12] - Over the past four quarters, Fox has beaten consensus EPS estimates three times [13] Industry Context - E.W. Scripps, another player in the Zacks Broadcast Radio and Television industry, is expected to report a loss of $0.23 per share, indicating a year-over-year change of -130% [17] - E.W. Scripps has an Earnings ESP of 0.00% and has not beaten consensus EPS estimates in any of the last four quarters [18]

Core Viewpoint - The market anticipates a year-over-year decline in earnings for Arcturus Therapeutics despite an increase in revenues, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - Arcturus Therapeutics is expected to report a quarterly loss of $1.13 per share, reflecting a year-over-year change of -13% [3]. - Revenues are projected to be $38.08 million, which is a slight increase of 0.2% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 5% over the last 30 days, indicating a bearish sentiment among analysts [4]. - The Most Accurate Estimate for Arcturus is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -9.49% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictive power for positive readings [6][7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically shown a nearly 70% chance of a positive surprise [8]. Historical Performance - In the last reported quarter, Arcturus was expected to post a loss of $0.34 per share but instead reported a loss of $1.11, resulting in a surprise of -226.47% [12]. - Over the past four quarters, Arcturus has beaten consensus EPS estimates three times [13]. Conclusion - Arcturus Therapeutics does not appear to be a strong candidate for an earnings beat based on current estimates and rankings, suggesting caution for investors [16].

Core Viewpoint - Regenxbio (RGNX) is anticipated to report a significant year-over-year increase in earnings and revenues for the quarter ended March 2025, which could influence its stock price depending on the actual results compared to estimates [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on May 12, 2025, with a consensus estimate of $0.41 per share, reflecting a year-over-year increase of +129.7% [3]. - Revenues are projected to reach $109.98 million, representing a substantial increase of 604.1% from the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 6.26%, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Regenxbio is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +57.77% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8]. - Regenxbio currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Regenxbio was expected to post a loss of $1.27 per share but actually reported a loss of $1.01, resulting in a surprise of +20.47% [12]. - Over the past four quarters, the company has surpassed consensus EPS estimates two times [13]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Sangamo Therapeutics (SGMO) is expected to report a loss of $0.11 per share for the same quarter, with a year-over-year change of +59.3% [17]. - Sangamo's revenue is projected to be $9.17 million, up 1810.4% from the previous year [17]. - Despite a recent downward revision of 23.8% in consensus EPS estimates, Sangamo has an Earnings ESP of 27.27%, but it holds a Zacks Rank of 4 (Sell), making predictions of an earnings beat uncertain [18].

Core Viewpoint - Opus Genetics, Inc. is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending March 2025, with the consensus outlook indicating a significant impact on the stock price based on actual results compared to estimates [1][3]. Financial Performance Expectations - The company is expected to post a quarterly loss of $0.34 per share, reflecting a year-over-year change of -17.2% [3]. - Revenues are projected to be $2.8 million, which represents a 63.7% increase from the same quarter last year [3]. Estimate Revisions and Predictions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [10]. Earnings Surprise History - In the last reported quarter, the company was expected to post a loss of $0.34 per share but instead reported a loss of $1.27, resulting in a surprise of -273.53% [12]. - Over the past four quarters, Opus Genetics has only beaten consensus EPS estimates once [13]. Industry Comparison - Cue Biopharma, another player in the Zacks Medical - Biomedical and Genetics industry, is expected to report a loss of $0.14 per share for the same quarter, indicating a year-over-year change of +44% [17]. - Cue Biopharma's revenues are expected to be $2 million, up 16.3% from the previous year, with an unchanged consensus EPS estimate over the last 30 days [17][18].

Company Overview - Veren (VRN) is expected to report a year-over-year increase in earnings of +31.8% to $0.29 per share, despite a revenue decline of 12.4% to $719.9 million for the quarter ended March 2025 [3][12] - The stock's price movement will largely depend on how actual results compare to consensus estimates, with a potential for higher stock prices if results exceed expectations [1][2] Earnings Estimates and Revisions - The consensus EPS estimate for Veren has been revised 25% higher in the last 30 days, indicating a bullish sentiment among analysts [4] - The Most Accurate Estimate for Veren is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +13.79%, suggesting a strong likelihood of beating the consensus EPS estimate [10][11] Earnings Surprise History - In the last reported quarter, Veren exceeded expectations by delivering earnings of $0.29 per share against an expected $0.24, resulting in a surprise of +20.83% [12] - Over the last four quarters, Veren has beaten consensus EPS estimates only once, indicating a mixed performance history [13] Industry Context - In the Zacks Oil and Gas - Integrated - Canadian industry, Cenovus Energy (CVE) is expected to report earnings of $0.29 per share, reflecting a year-over-year decline of -37%, with revenues projected at $9.55 billion, down 3.9% [17] - Cenovus has seen a 1.6% downward revision in its consensus EPS estimate over the last 30 days, and its Earnings ESP is currently at 0.00%, making it difficult to predict a beat against consensus estimates [18]

Core Viewpoint - The market anticipates Costamare (CMRE) will report a year-over-year decline in earnings due to lower revenues for the quarter ended March 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Costamare is expected to post quarterly earnings of $0.52 per share, reflecting a year-over-year decrease of 17.5% [3]. - Revenues are projected to be $412.67 million, down 13.2% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 17% higher in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Costamare is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +6.80% [10][11]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a potential earnings beat, especially when combined with a strong Zacks Rank [8]. - However, Costamare currently holds a Zacks Rank of 4, complicating the prediction of an earnings beat despite the positive Earnings ESP [11]. Historical Performance - In the last reported quarter, Costamare exceeded the expected earnings of $0.66 per share by delivering $0.69, resulting in a surprise of +4.55% [12]. - The company has beaten consensus EPS estimates in each of the last four quarters [13]. Industry Context - In the Zacks Transportation - Shipping industry, Ardmore Shipping (ASC) is expected to report earnings of $0.15 per share, indicating a year-over-year decline of 83.7% [17]. - Ardmore Shipping's consensus EPS estimate has been revised 37.8% lower in the last 30 days, leading to an Earnings ESP of -10.35% [18].

Core Viewpoint - The market anticipates Cheniere Energy (LNG) will report a year-over-year increase in earnings driven by higher revenues when it releases its quarterly results for the period ending March 2025 [1] Earnings Expectations - Cheniere Energy is expected to report quarterly earnings of $2.81 per share, reflecting a year-over-year increase of +31.9% [3] - Revenues are projected to be $4.47 billion, which is a 5.2% increase from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised down by 9.73% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Cheniere Energy matches the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [10][11] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictor for positive readings [7][8] - Cheniere Energy's current Zacks Rank is 3 (Hold), making it challenging to predict an earnings beat conclusively [11] Historical Performance - In the last reported quarter, Cheniere Energy was expected to post earnings of $2.69 per share but delivered $4.33, resulting in a surprise of +60.97% [12] - Over the past four quarters, the company has beaten consensus EPS estimates three times [13] Industry Comparison - Civitas Resources (CIVI), another player in the Oil and Gas - Exploration and Production sector, is expected to report earnings of $1.68 per share for the same quarter, indicating a year-over-year decline of -3.5% [17] - Civitas has seen a 24.4% downward revision in its consensus EPS estimate over the last 30 days, but a higher Most Accurate Estimate has resulted in an Earnings ESP of 0.17% [18]

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for E.W. Scripps due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - E.W. Scripps is expected to report a quarterly loss of $0.23 per share, reflecting a year-over-year change of -130% [3]. - Revenues are projected to be $519.5 million, down 7.5% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 61.11% higher in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likelihood of deviation from consensus estimates, with positive readings being more predictive of earnings beats [6][7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have shown a nearly 70% success rate in delivering positive surprises [8]. Historical Performance - E.W. Scripps has not beaten consensus EPS estimates in the last four quarters, with the most recent quarter showing a surprise of -2.02% [12][13]. Conclusion - E.W. Scripps does not appear to be a strong candidate for an earnings beat, and investors should consider other factors when evaluating the stock ahead of its earnings release [16].